A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants
Phase 1
Completed
NCT04194892
| Condition | Healthy Adult Subjects |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Eli Lilly and Company |
|---|
| Status | Completed |
|---|
| Enrollment | 12 participants |
|---|
| Interventions | Pegilodecakin |
|---|
| Start date | Jan 19, 2018 |
|---|
| Completion date | Mar 14, 2018 |
|---|
| Results posted | Jul 13, 2026 |
|---|
Summary
The purpose of this study is to assess how fast pegilodecakin gets into the blood stream and how long it takes the body to remove it, when given as a solution formulation via a prefilled syringe (PFS) versus from a vial drawn into a conventional syringe. Information about side effects will be collected. The study is open to healthy participants. Total participant duration in trial is approximately 42 days.
Pharmacokinetic (PK): Maximum Drug Concentration (Cmax) of Pegilodecakin
Period 1: Days 1 to 4 and Day 8 (Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose (Day 8-predose)), Period 2: Days 8 to 11 and Day 15 (Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose) · picogram per milliliter (pg/mL)
| Pegilodecakin Vial | 9050 ± 93.7 picogram per milliliter (pg/mL) |
|---|
| Pegilodecakin Pre-filled Syringe (PFS) | 12000 ± 111 picogram per milliliter (pg/mL) |
|---|
PK: Time of Maximum Concentration (Tmax) of Pegilodecakin
Period 1: Days 1 to 4 and Day 8 (Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose (Day 8-predose)), Period 2: Days 8 to 11 and Day 15 (Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose) · hours
| Pegilodecakin Vial | 12.00 hours |
|---|
| Pegilodecakin Pre-filled Syringe (PFS) | 12.00 hours |
|---|
PK: Area Under the Serum Concentration Versus Time Curve From Time Zero to Infinity AUC[0-inf] of Pegilodecakin
Period 1: Days 1 to 4 and Day 8 (Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose (Day 8-predose)), Period 2: Days 8 to 11 and Day 15 (Predose, 2, 4, 8, 12, 16, 24, 36, 48, 72, and 168 hours post-dose) · hour*picogram per milliliter (h*pg/mL)
| Pegilodecakin Vial | 304000 ± 66.6 hour*picogram per milliliter (h*pg/mL) |
|---|
| Pegilodecakin Pre-filled Syringe (PFS) | 457000 ± 62.8 hour*picogram per milliliter (h*pg/mL) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.